Skip to content

Clinical trials

Observational Autoimmune Diseases trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Autoimmune Diseases Phase: Observational Country / region: France Clear all

38 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20091
20101
20123
20131
20151
20161
20171
20183
20192
20204
20219
20224
20231
20241
20253
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed15
Recruiting12
Unknown status6
Not yet recruiting2
Terminated2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Assistance Publique - Hôpitaux de Paris5
University Hospital, Brest4
Institut National de la Santé Et de la Recherche Médicale, France3
University Hospital, Montpellier3
University Hospital, Strasbourg, France3
Centre Hospitalier Universitaire de Saint Etienne2
Centre Hospitalier Universitaire, Amiens2
European Society for Blood and Marrow Transplantation2
Imagine Institute2
University Hospital, Lille2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Autoimmune Diseases38
Immune System Diseases6
Lupus Erythematosus, Systemic5
COVID-194
Nervous System Diseases4
Scleroderma, Systemic4
Diabetes Mellitus, Type 13
Genetic Diseases, Inborn3
Infections3
Arthritis2

Trials

Showing 1 to 25 of 38. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.